Requires cost sharing amounts for certain prescription drug benefits to be based on final cost to carrier.
Impact
If enacted, S3703 will directly affect health benefits plans issued or renewed beginning January 1 of the year following its enactment. Its primary impact lies in potentially lowering out-of-pocket costs for covered individuals by adjusting cost sharing in accordance with the actual price that the carrier pays. This amendment to existing law (P.L.2015, c.179) is designed to enhance transparency in healthcare pricing and improve the financial burden on consumers when it comes to prescription medications.
Summary
Senate Bill 3703, introduced in New Jersey, is focused on prescription drug benefits and establishes a requirement for cost sharing amounts to be based on the final cost to the carrier. The bill aims to simplify and clarify how covered individuals are charged for prescription medications by ensuring that these charges reflect the true costs incurred by insurance carriers. This includes any negotiations that may occur between the carriers and pharmacy benefits managers, as well as any financial incentives that may be provided by pharmaceutical manufacturers, such as rebates or discounts.
Contention
While the bill seeks to introduce positive changes for consumers, it may not be without contention. There may be concerns raised regarding how these changes affect the relationship between carriers, pharmacy benefits managers, and pharmaceutical manufacturers. Stakeholders in the healthcare sector, such as insurance companies and drug manufacturers, may express apprehensions regarding the implications of mandated pricing structures, questioning the sustainability and fiscal feasibility of implementing such requirements. Furthermore, there could be debates surrounding the potential for increased costs for insurance providers, which, in turn, might affect premium rates for consumers.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.